
News & Events
News & Events
-
September 18, 2023
C-Path and EATRIS Join Forces with New Collaboration Agreement
AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastructure for Translational Medicine) are pleased to announce the signing of a collaboration agreement aimed at fostering actionable scientific and educational cooperation. This agreement marks a significant milestone in the pursuit of patient-centric innovation and the advancement of... -
August 25, 2023
C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials
This memo outlines how C-Path can contribute as a key strategic regulatory partner to the Innovative Health Initiative’s (IHI) call 4, “Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases.” We encourage potential partners to review the memo and reach out as early as possible to rdcadap@c-path.org with interest. On 27 July 2023, the... -
July 19, 2023
The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development
TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path. Angelman... -
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.
-
June 7, 2023
Newcastle University’s John Walton Muscular Dystrophy Research Centre Contributes Data to C-Path’s RDCA-DAP
C-Path announced today that Newcastle University UK’s John Walton Muscular Dystrophy Research Centre will contribute data to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) managed by C-Path. These data come from the Myotubular (MTM) and Centronuclear Myopathy (CNM) Patient Registry and the Global Registry for COL6-related dystrophies.